In univariable analysis (exp, 95% IC, p) female sex was associated with smaller core (0.571, 0.448-0.729, 6 H) Agathe Sadeler 1 , Stefanos Finitsis 2 , Jean Marc Olivot 3 , Sbastien Richard 4,5 , Gaultier Marnat 6 , Igor Sibon 7 , Lionel Calviere 3 , Christophe Cognard 8 , Mikael Mazighi 9,10,11,12 , Jean Philippe Desilles 9,11,12,13 , Bertrand Lapergue 14 , Ruben Tamazyan 1,13 , Mathieu Zuber 1,11,13 , Benjamin Gory 15,16 , Benjamin Maer 1,9,11,12 1 Neurology Department, Hpital Saint-Joseph, Paris, France, 2 Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece, 3 Vascular Neurology Department, CIC 1436, University Hospital of Toulouse, Toulouse, France, 4 Department of Neurology, Stroke Unit, Universit de Lorraine, CHRU-Nancy, Nancy, France, 5 CIC-P 1433, INSERM U1116, CHRU-Nancy, Nancy, France, 6 Department of Diagnostic and Interventional Neuroradiology, University Hospital of Bordeaux, Bordeaux, France, 7 Neurology Department, University Hospital of Bordeaux, Bordeaux, France, 8 Department of Neuroradiology, CHU Toulouse, Toulouse, France, 9 Interventional Neuroradiology Department, Hpital Fondation A
Find your treatment Compounded by state-licensed 503A pharmacies
Key dosing points from the study: Dose range: 200500 mcg per session (individual variation based on severity and body weight) Frequency: 23 sessions per week during the active treatment phase Duration: 48 weeks of active treatment Route: Local subcutaneous injection proximal to the affected joint Concurrent therapy: Most patients continued physical therapy alongside BPC-157 treatment The combination of local administration and physical therapy aligns with the hypothesis that BPC-157 accelerates structural repair while functional loading (exercise) guides proper tissue remodeling
Of the 40 patients (21%) who had baseline serum MMA levels, five had a serum B 12 250 pg/mL
